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Platelet activating factor (PAF), a potent inﬂammatory mediator, is implicated in several proinﬂammatory/inﬂammatory diseases
such as glomerulonephritis, glomerulosclerosis, atherosclerosis, cancer, allergy, and diabetes. PAF can be produced by several renal
cells under appropriate stimuli and it is thought to be implicated in renal diseases. The aim of this study is the characterization
of DTT-insensitive cholinephosphotransferase (PAF-CPT) of human mesangial cell (HMC), the main regulatory enzyme of PAF
de novo biosynthetic pathway. Microsomal fractions of mesangial cells were isolated and enzymatic activity and kinetic parame-
ters were determined by TLC and in vitro biological test in rabbit washed platelets. The eﬀect of bovine serum albumin (BSA),
dithiothreitol (DTT), divalent cations (Mg2+ and Ca2+), EDTA, and various chemicals on the activity of PAF-CPT of HMC was
also studied. Moreover, preliminary in vitro tests have been performed with several anti-inﬂammatory factors such as drugs (sim-
vastatin, IFNa, rupatadine, tinzaparin, and salicylic acid) and bioactive compounds of Mediterranean diet (resveratrol and lipids
of olive oil, olive pomace, sea bass “Dicentrarchus labrax,” and gilthead sea bream “Sparus aurata”). The results indicated that the
above compounds can inﬂuence PAF-CPT activity of HMC.
Copyright © 2007 Alexandros Basilios Tsoupras et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
Platelet activating factor (PAF, 1-O-alkyl-2-acetyl-sn-
glycero-3-phosphocholine) [1–3], a potent phospholipid
mediator with a wide variety of biological activities, is
involved in a number of proinﬂammatory/inﬂammatory
manifestations, such as glomerulonephritis, glomeruloscle-
rosis, atherosclerosis, cancer, allergy, and diabetes.
Many diﬀerent cells, including leukocytes, platelets,
macrophages, neutrophils, lymphocytes, endothelial cells,
and renal cells can produce PAF under appropriate stim-
uli [4]. Two enzymatic pathways of PAF biosynthesis have
been described [5]. The de novo pathway entails a speciﬁc
stepwise sequence of reactions ending with a transfer of the
phosphocholine base group from CDP-choline to 1-O-alkyl-
2-acetyl-sn-glycerol (AAG) by a dithiothreitol- (DTT-) in-
sensitivecholinephosphotransferase(PAF-CPT),whileinthe
remodeling pathway the ﬁnal step includes an acetylation of
l-alkyl-2-lyso-sn-glycero-3-phosphocholine (Lyso-PAF) by a
speciﬁc acetyltransferase (Lyso-PAF-AT). On the other hand,
themainenzymeforPAFdegradationisPAF-acetylhydrolase
(PAF-AH) [6].
In general, it has been proposed that the de novo path-
way should mainly contribute to PAF synthesis for maintain-
ing its basal levels under physiological conditions, whereas
the remodeling pathway should be more involved in the pro-
duction of PAF during inﬂammatory responses [7, 8]. How-
ever,theinformationcollectedsofarconcerningPAFbiosyn-
thetic pathways suggest that the contribution of the afore-
mentioned enzymes to PAF synthesis depends on several fac-
tors under physiological and pathological conditions [8–13],
and so the above point of view should be reevaluated and
further studied.
The important regulatory enzyme of the de novo route,
PAF-CPT, is widely distributed among mammalian tissues
and is located on the cytoplasmic surface of the endoplasmic
reticulum [8]. It has been found in a variety of rat tissues
[7, 8, 12, 14] with the spleen, lung, liver, and kidney exhibit-
ing the highest activities. Human renal cell carcinoma [13],2 Mediators of Inﬂammation
porcine spleen [11], as well as human neutrophils, human
cerebrum, fetal rabbit lungs, and unfertilized mouse oocytes,
zygotes, and preimplantation embryos [8, 15] also contain
signiﬁcant amounts of PAF-CPT.
PAF-CPT has been solubilized from porcine spleen mi-
crosomes using digitonin [11]. Although the activity of
the solubilized enzyme was relatively stable, further pu-
riﬁcation by sequential chromatography caused a remark-
able decrease in enzyme activity, which was partially re-
covered by the exogenously addition of phospholipids such
as egg phosphatidylcholine, and so forth. [11]. In contrast,
dioleoylphosphatidic acid (DOPA) and lysophospholipids
showed an inhibitory eﬀect on enzyme activity [11]. The
molecular weight of the enzyme solubilized from porcine
spleen microsomes was estimated to be 440 kd based on gel-
ﬁltration column chromatography, suggesting that this en-
zyme formed a complex with other protein molecules and
membranephospholipids,andthatthesephospholipidswere
necessary to maintain the enzyme activity [11].
Although PAF-CPT and the cholinephosphotransferase
involved in phosphatidylcholine synthesis (PC-CPT) have
several common features, however signiﬁcant diﬀerences be-
tween the two enzymes concerning their behavior to deter-
gents, DTT, ethanol, pH [8], as well as interactions with en-
vironmental membrane phospholipids containing phospha-
tidic acid (PA) and/or lysophospholipids [11]h a v eb e e no b -
served. All the above data support the hypothesis that PAF-
CPT is a separate enzyme from PC-CPT, although further
studies are required.
Investigation of PAF-CPT substrate speciﬁcity of sev-
eral alkylacetylglycerol substrates has shown that the enzyme
prefers alkyl substrates possessing either an acetyl or propi-
onyl group at the sn-2 position. Also, an analog of alkylacetyl
glycerol containing a methoxy substitution at the sn-2 posi-
tion is not a substrate of PAF-CPT [8].
In the kidney, both de novo and remodeling biosynthetic
routes can produce PAF either by intrinsic glomerular cells
such as mesangial cells [16] or by inﬁltrating inﬂammatory
cells.ApartfromPAFphysiologicaleﬀects,itsincreasedlevels
inkidney areinvolved inthepathogenesis andprogressionof
renal damage [17–19]. The study of PAF metabolic enzymes
in kidney, especially in mesangial cells, is of great importance
since they regulate PAF levels both intracellularly and extra-
cellularly.
In our previous studies, PAF-AH as well as remodeling
and de novo acetyltransferases have been previously char-
acterized in cortex and medulla from human kidney tissue
[20–22], while remodeling PAF acetyltransferases have been
characterized in human mesangial cells [23]. Although PAF
metabolism has been described in mesangial cells [24, 25],
as far as we know there are no direct studies on PAF-CPT in
mesangial cells. The aim of the present work was a biochem-
ical characterization of PAF-PCT in mesangial cells. More-
over, the eﬀects of several bioactive compounds of Mediter-
ranean diet and various drugs on PAF-CPT activity were
tested in order to evaluate a possible beneﬁcial eﬀect of these
factors on renal disorders.
2. MATERIALS AND METHODS
2.1. Materialsandinstrumentation
Centrifugations were performed in a Heraeus Labofug 400R
and a Sorvall RC-5B refrigerated superspeed centrifuge
(Sigma-Aldrich, St. Louis, Mo, USA) apart from the cen-
trifugation at 100000×g, which was performed in a Heraeus-
Christ, Omega 70000 ultracentrifuge (Hanau, Germany).
Homogenizations were conducted at 40KHz with a VC50 su-
personic sonicator of Sonics & Materials. (Sonics & Materi-
als, Inc., Conn, USA). Aggregation studies were performed
in a Chronolog aggregometer (model 400) (Havertown, Pa,
USA) coupled to a Chrono-Log recorder (Havertown, Pa,
USA) at 37◦C with constant stirring at 1200rpm.
The electrospray ionization (ESI) mass spectrometry ex-
periments were performed on an Electronspray MS-LCQ-
Deca (Thermo Finnigan Ltd., Hertfordshire, UK), low ﬂow,
and mass spectrometer. Samples were dissolved in a small
volume of HPLC grade methanol/water (70:30, v/v) 0.01M
in ammonium acetate. Electrospray samples are typically in-
troduced into the mass analyzer at a rate of 3μL/minute.
Nitrogen of purity 99.99% is used as nebulizing gas and as
bath gas with ﬂow rate of 3μL/minute. The spectrum anal-
ysis was contacted in the ion space of 50–1500m/z and the
conditions for the highest intensity of the summits with the
lowest rupture were those that are shown below: spray volt-
age:5kV,capillaryvoltage:7V,capillarytemperature:275◦C,
lens-entrance voltage: −54V, lens voltage: −22V.
1-O-alkyl-2-sn-acetyl-glycerol (AAG) was purchased
from BIOMOL International, L.P., Palatine House, Mat-
ford Court, Exeter, UK. CDP-choline, dithiothreitol (DTT),
EDTA, MgCl2, analytical solvents, and Silica G for TLC
method were purchased from Sigma Chemicals Co. and
Merck KGaA Darmstadt Germany, respectively.
Bioactive lipid extracts of olive oil, olive pomace, sea
bash, and sea bream were isolated as previously described
[26, 27].
2.2. Cellculture
An established stable human mesangial cell line (HMC) was
used in all the experiments (kindly donated by Dr Z. Vargh-
ese, Royal Free and University Collage Medical School, Lon-
don, United Kingdom). HMCs were immortalized by trans-
fection with T-SV40 and Hras oncogene, retaining many of
the morphological and physiological features of normal hu-
man mesangial cells [28]. The cells were cultured as previ-
ously described [23] in medium containing RPMI 1640, 5%
FCS, glutamine (2mmol/L), penicillin (105unit/L), strep-
tomycin (0.1g/L), amphotericin (2.5 × 10
−3 g/L), insulin-
transferrin(5×10
−3 g/L),andsodiumselenite(5×10
−6 g/L).
2.3. Homogenizationofmesangialcellsand
preparationofsubcellularfractions
Homogenization of mesangial cells and preparation of sub-
cellular fraction were carried out as previously described
[23]. Brieﬂy, mesangial cells were cultured in 75cm2 ﬂasks,Alexandros Basilios Tsoupras et al. 3
Table 1: Subcellular speciﬁc activity of PAF-CPT from human
mesangial cell preparations (n = 3).
Subcellular fractions PAF-CPT speciﬁc activity
(nmol/min/mg)
Homogenate fractions
(500×g supernatant) 0.10 ±0.05
Mitochondrial fractions
(20000×g pellet) 0.02 ±0.01
Cytoplasmic fractions
(100000×g supernatant) Nondetected
Microsomal fractions
(100000×g pellet) 0.36 ±0.20
the pellet of the cells was resuspended in homogenization
buﬀer containing 0.25M sucrose, 10mM EDTA, 5mM mer-
captoethanol, 50mM NaF, 50mM Tris-HCl (pH 8), and was
homogenized by sonication in −4◦C. The homogenates were
centrifuged at 500×g for 10 minutes to remove nucleus,
whole cells, and debris. The pellets were discarded, a small
portion of the supernatants was kept for protein determina-
tion and the rest of them were centrifuged at 20000×g for
20 minutes to remove mitochondria. Microsomes were iso-
lated from cell homogenates after centrifugation of the ﬁnal
supernatant at 100000×g for 60 minutes. The resulting pel-
lets were suspended in suspension buﬀer containing 0. 25M
sucrose, 1mM DTT, 50mM Tris-HCl (pH 8), a small portion
of the suspended microsomal pellet was kept for protein de-
terminationandtherestwerealiquotedandstoredat −20◦C.
All homogenization and fractionation procedures have taken
place at −4◦C.
2.4. DTT-insensitivecholinephosphotransferase
(PAF-CPT)activityassays
DTT-insensitive CDP-choline:l-alkyl-2-acetyl-sn-glycerol
cholinephosphotransferase (PAF-CPT) was assayed at 37◦C
for 20 minutes in a ﬁnal volume of 200μL of reaction mix-
ture containing 0.025–0.1mg/mL of microsomal protein,
100mM Tris-HCl (pH 8.0), 15mM DTT, 0, 5mM EDTA,
20mM MgCl2, 1mg/mL of BSA, 100μM of CDP-choline,
and 100μ of AAG (added in the mixture in 2μL of ethanol).
Variations in the incubation conditions, where needed, are
noted in the ﬁgures and table legends.
The reactions were stopped by adding methanol (con-
taining 2% acetic acid). The extraction and the puriﬁcation
of PAF were performed as previously described [21]. Brieﬂy,
the lipid products were extracted into chloroform according
tothemethodofBlighandDyer[29],whiletheseparationof
thelipidextractswasachievedbyaTLCmethodonSilicaGel
G in chloroform:methanol:acetic acid:water (100:57:16:8,
v/v).LipidfractionswerevisualizedbyI2 exposureandphos-
pholipidproductswereidentiﬁedbycochromatographywith
known standards. PAF fractions were scrapped oﬀ and ex-
tracted with chloroform according to the method of Bligh
and Dyer [29].
The PAF solutions in chloroform were evaporated un-
der a stream of nitrogen, redissolved in BSA (0.25% w/v
in saline), and the produced PAF levels were estimated by
washed rabbit platelet aggregation [1]. This procedure was
used for all the quantitive determinations mentioned in re-
sults. The TLC fraction with PAF-like activity was subjected
to ESMS analysis.
I no r d e rt os t u d yt h ei nv i t r oe ﬀect of drugs and food
extracts on PAF-CPT activity, these factors were dissolved in
40mg/mL of BSA and then added on the reaction mixture.
PAF-CPT enzymatic assay was performed in the presence of
several concentrations of each factor in the reaction mixture
(while BSA concentration in all cases was 1mg/mL).
2.5. Analyticalmethods
Protein concentrations,determined accordingtoLowryetal.
[30], were based on bovine serum albumin as the protein
standard.
2.6. Recoveryofthemethod
In order to evaluate the percentage of the recovery of the
product (PAF) of the enzymatic reaction from all the above
steps and procedures of this method, the microsomal frac-
tion was heated at 100◦C for 20 minutes and the inactive
microsomal protein was added in the above-mentioned re-
action mixture that also contains speciﬁc concentration of
standard PAF. This experiment was performed six times. Es-
timation of PAF levels from these experiments was carried
out as mentioned above. The percentage of the recovery of
the product (PAF) of the enzymatic reaction from all the
above steps and procedures of this method has a mean value
of 62.20 ± 5.32%. This value was taken into account in the
calculation of all PAF-CPT activities.
2.7. Statisticalanalysis
Data are expressed as mean values ± SD using Microsoft Ex-
cel. The linear or nonlinear regressions of enzymes kinetics
were also made using Microsoft Excel.
3. RESULTS
3.1. PAF-CPTactivityofHMC
PAF-CPT activity was determined by produced PAF levels
that were separated by TLC. The TLC fraction with PAF-like
activity gave identical ESMS fragments to the ones of syn-
thetic PAF (16:0), M.W.: 524 (data not shown).
The speciﬁc activity of PAF-CPT of HMC was detected
mainly in the microsomal fraction (100 000×g pellet) with
av a l u eo f0 .36 ± 0.20nmol/mg/min. It was also detected in
thehomogenatefractions(500×g), andinthemitochondrial
fractions (20000×g), in a lower range. PAF-CPT activity was
not detected in the cytoplasmic fractions (100 000×g super-
natants). The results are shown in Table 1.A l ls u b s e q u e n t
experiments were performed with microsomal preparations.
PAF-CPT speciﬁc activity was stable for a period of 30 days
and was reduced at 50% after 45-day storage at −20◦C, re-
spectively.4 Mediators of Inﬂammation
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Figure 1: Eﬀect of pH on PAF-CPT speciﬁc activity of mesangial
cells: microsomal fractions of HMC 0.05mg/mL were incubated in
the presence of diﬀerent buﬀer solutions. Results are the average of
two independent determinations using diﬀerent enzyme prepara-
tions performing duplicate samples.
3.2. EffectoftemperatureandpHonPAF-CPTactivity
ofHMC
Experimentswerecarriedoutinordertofoundtheoptimum
conditions for the action of the enzyme. The temperature ac-
tivityproﬁleswerebell-shapedshowinganoptimumat37◦C.
Heating of samples at 50◦Ca n d6 0 ◦C for 20 minutes resulted
in 80% and 100% inactivation of the existing enzyme activ-
ity, respectively.
In order to investigate the dependence of PAF-CPT
activity on pH, four diﬀerent buﬀer solutions of var-
ious pH values were utilized, namely, 100mM acetic
(CH3COOH−CH3COONa) buﬀer pH 4–6, 100mM phos-
phate (NaH2PO4−Na2HPO4)b u ﬀer pH 6–7, 100mM Tris-
HClbuﬀerpH7–9,and100mMGlycinebuﬀerpH9–10.The
pH activity proﬁle was bell-shaped showing an optimum pH
range at 8. The results are shown in Figure 1.
3.3. EffectofBSAonPAF-CPTactivityofHMC
Microsomal fractions of HMC 0.05mg/mL were incubated
in the presence of diﬀerent concentrations of BSA in a
range of 0.1–2mg/mL in the reaction medium. As shown in
Figure 2, PAF synthesis is increased (P<. 05) at BSA concen-
trations ranging from 0.5 to 2.
3.4. Effectofdithiothreitol(DTT)onPAF-CPT
activityofHMC
Microsomal fractions of HMC 0.05mg/mL were incubated
in the presence of diﬀerent concentrations of DTT in a
range of 0.01–20mM in the reaction medium. As shown in
Figure 3, PAF synthesis is slightly increased (P>. 05) at DTT
concentrations above 1mM; it exhibits optimal stimulation
at 15mM DTT.
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Figure 2: Eﬀect of BSA concentration on PAF-CPT speciﬁc activ-
ity of mesangial cells: microsomal fractions of HMC 0.05mg/mL
were incubated in the presence of diﬀerent concentrations of BSA.
Results are the average of two independent determinations using
diﬀerent enzyme preparations performing duplicate samples.
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Figure 3: Eﬀect of DTT concentration on PAF-CPT speciﬁc activ-
ity of mesangial cells: microsomal fractions of HMC 0.05mg/mL
were incubated in the presence of diﬀerent concentrations of DTT.
Results are the average of two independent determinations using
diﬀerent enzyme preparations performing duplicate samples.
3.5. EffectofdivalentcationsandEDTAandseveral
chemicalsonPAF-CPTactivityofHMC
Microsomal fractions of HMC 0.05mg/mL were incubated
in the presence of diﬀerent concentrations of both cations in
the absence or in the presence of the chelate reagent EDTA.
The results are summarized in Tables 2 and 3. The highest
activity was obtained with 20mM Mg2+in the presence of
0.5mM EDTA (P<. 05), which was routinely used. In con-
trast, Ca2+levels of 0.1mM caused inhibition of PAF-CPT in
the absence of EDTA (P<. 05), which was partially reduced
by the presence of the chelate reagent.
InordertostudytheeﬀectofEDTAconcentrationonthe
PAF-CPT activity of HMC, microsomal fractions of HMCAlexandros Basilios Tsoupras et al. 5
Table 2: Eﬀect of Mg2+ cation on PAF-CPT activity of HMC. Results represent the average of two independent experiments using diﬀerent
enzyme preparations performing duplicate samples.
Mg2+cation Concentration in assay (mM) PAF-CPT speciﬁc activity (nmol/min/mg)
Exogenous Mg2+ ([EDTA] = 0) 0 Not detected
Exogenous Mg2+ ([EDTA] = 0) 0.1 0.0003
Exogenous Mg2+ ([EDTA] = 0) 1 0.0012
Exogenous Mg2+ ([EDTA] = 0) 10 0.0036
Exogenous Mg2+ ([EDTA] = 0) 20 0.067
Exogenous Mg2+ ([EDTA] = 0.5mM) 20 0.25
Table 3: Eﬀect of Ca2+ cation on PAF-CPT activity of HMC. Results represent the average of two independent experiments using diﬀerent
enzyme preparations performing duplicate samples.
Ca2+ cation Concentration in assay (mM) PAF-CPT activity (%)
Exogenous Ca2+ ([EDTA] = 0.5mM, [Mg2+] = 20mM) 0 100
Exogenous Ca2+ ([EDTA] = 0, [Mg2+] = 20mM) 0 67.4
Exogenous Ca2+ ([EDTA] = 0, [Mg2+] = 20mM) 0.1 14.1
Exogenous Ca2+ ([EDTA] = 0.5mM, [Mg2+] = 20mM) 0.1 33.3
Exogenous Ca2+ ([EDTA] = 0, [Mg2+] = 20mM) 1 1.41
Exogenous Ca2+ ([EDTA] = 0.5mM, [Mg2+]= 20mM) 1 3.70
0.05mg/mL were incubated in the presence of diﬀerent con-
c e n t r a t i o n so fE D T Ai nar a n g eo f0 . 0 1 – 1 0m M ,a sw e l la s
in the presence of 20mM Mg2+, in the reaction medium. As
shown in Figure 4, the maximum enzyme activity occurred
at 0.5mM EDTA ﬁnal concentration in reaction medium,
which was routinely used. Concentration of EDTA of 10mM
abolished PAF-CPT activity.
In conclusion, the presence of 1mg/mL BSA, 15mM
DTT, 20mM Mg2+, and 0.5mM EDTA in the reaction
medium of PAF-CPT assay resulted in maximum activity,
and was routinely used.
3.6. Effectofchemicals(NaFandPefabloc)on
PAF-CPTactivityofHMC
Thepresenceof50mMofNaF,aproteaseinhibitor,inthere-
action medium reduced PAF-CPT activity up to 40%, while
the presence of 0.1mM of Pefabloc, a sulfonyl-type serine
protease inhibitor, had no signiﬁcant eﬀect on the enzyme
action suggesting the absence of serine(s) in the active site of
the enzyme.
3.7. DependenceofPAFformationbyprotein
concentrationandincubationtime
ThekineticsofPAFformationinrelationtotimeandprotein
concentration is shown in Figure 5. The total amount of PAF
formed at the end of each incubation time decreased as pro-
tein concentration decreased (Figure 5(a)). A linear relation-
shipbetweentheinitialvelocityandtotalmicrosomalprotein
up to 0.1mg/mL was found for 20 minutes incubation time
(Figure 5(b)). In order to achieve the maximum yield of re-
action, 0.05mg/mL protein and 20-minute incubation time
were routinely used.
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Figure 4: Eﬀect of the concentration of the chelate reagent EDTA
in the presence of 20mM Mg2+ on PAF-CPT speciﬁc activity of
mesangial cells:microsomalfractionsofHMC0.05mg/mLwerein-
cubatedinthepresenceofdiﬀerentconcentrationsofEDTA.Results
are the average of two independent determinations using diﬀerent
enzyme preparations performing duplicate samples.
3.8. EffectofsubstratesconcentrationonPAF-CPT
activityandkineticparameters
The activity of PAF-CPT was determined at diﬀerent AAG
concentrations ranging from 2 to 400μMa taﬁ x e dc o n c e n -
tration of CDP-choline 100μM( Figure 6(a)) and at diﬀer-
ent CDP-choline concentrations ranging from 2 to 200μM
at a ﬁxed concentration of AAG 100μM( Figure 6(b)). The
results revealed that enzyme exhibited classical Michaelis-
Menten kinetics with respect to AAG as well as to CDP-
choline. The kinetic parameters of the enzyme showed on
Figure 6 were calculated using Lineweaver-Burk plot.6 Mediators of Inﬂammation
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Figure 5: Dependence of PAF formation on incubation time and
protein concentration: (a) time course of PAF production using
0.025, 0.05, and 0.1mg total protein/mL; (b) CPT activity as a func-
tion of protein concentration at a ﬁxed incubation time of 20 min-
utes. Experiments were performed with microsomal fractions of
HMC in the presence of 100μM AAG and 100μM CDP-choline.
Results are the average of two independent determinations using
diﬀerent enzyme preparations performing duplicate samples.
3.9. Effectofvariousdrugsandlipidextracts
In order to examine the in vitro eﬀect on PAF-CPT activity
of various drugs and lipid extracts of nutrients of Mediter-
ranean diet, preliminary experiments were conducted. Mi-
crosomal fractions were isolated from HMC and the enzy-
matic assay of PAF-CPT was performed in the presence of
several concentrations of each compound in the reaction
mixture. The concentration of each compound that inhib-
ited the maximum inhibitory eﬀectagai n stP AF -C PTacti vi ty
is represented on Table 4. Drug trade names and food origin
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Figure 6: Eﬀect of substrate concentration on PAF-CPT activity:
(a) activity of PAF-CPT as a function of AAG at ﬁxed concentra-
tion of CDP-choline (100μM) and the relative Lineweaver-Burk
plot; (b) activity of PAF-CPT as a function of CDP-choline at ﬁxed
concentration of AAG (100μM) and the relative Lineweaver-Burk
plot. Experiments were performed at microsomal fractions using
0.05mg/mL protein in optimum conditions. Results represent the
average ± SD of three independent determinations using diﬀerent
enzyme preparations performing duplicate samples.
of the bioactive compounds, as well as their reported biolog-
ical actions, are also shown on Table 4.
4. DISCUSSION
In this study, the presence of PAF-CPT activity in HMC was
detected for the ﬁrst time. Moreover, the characterization
of PAF-CPT of HMC was also performed for the ﬁrst time.
In order to evaluate PAF-CPT activity of HMC, a new en-
zymatic assay procedure was achieved. In contrast with all
previous reported enzymatic assays for the determination of
PAF-CPT, (a) in this assay the amount of the added sam-
ple protein in the reaction mixture is much lower, giving the
opportunity to detect PAF-CPT activity in samples with lowAlexandros Basilios Tsoupras et al. 7
Table 4: In vitro eﬀects of various drugs and bioactive compounds of Mediterranean diet on PAF-CPT activity of HMC. Preliminary
results represent the average of two independent experiments using diﬀerent enzyme preparations performing duplicate samples. Results are
expressed as percentage of inhibition of PAF-CPT activity versus control (absence of these factors).
Bioactive compound Drug name/food origin Action Concentration in assay Inhibition of PAF-CPT (%)
Rupatadine Rupaﬁn (i) Antiallergic [31] 20ng/μL6 0
(ii) PAF-antagonist [31]
Simvastatin Zocor (i) Antiatherogenic [32] 40ng/μL9 2
(ii) Anticancer [33]
INFa IntronA Anticancer [34] 250IU/μL5 1
Tinzaparin Innohep (i) Antithrombotic [35] 0.25IU/μL3 0
(ii) Anticancer [36]
Salicylic acid Aspirin (i) Anti-inﬂammatory [37] 250ng/μL3 8
(ii) Anticancer [38]
Resveratrol —
(i) Antioxidant [39]
100μM3 9 (ii) Anti-PAF [39]
(iii) Anticancer [39]
Polar lipids Olive oil
(i) Antiatherogenic [40]
5.2ng/μL3 3 (ii) Anti-PAF [40]
(iii) Anticancer [41]
Polar lipids Olive pomace (i) Antiatherogenic [26, 40] 1.8ng/μL4 8
(ii) Anti-PAF [26, 40]
Polar lipids Sea bass Anti-PAF [27]5 9 n g / μL4 5
Polar lipids Sea bream Anti-PAF [27] 123ng/μL1 7
protein distribution, (b) this assay does not need the use of
radiolabeled compounds, reducing though the risk and ex-
pense of the procedure.
According to this assay, PAF-CPT activity was detected
mainly in the microsomal fraction and its biochemical char-
acteristics were found similar to previously published data
from other groups in other types of cells and tissues [7–
12, 14, 15]. Speciﬁcally, PAF-CPT activity is signiﬁcantly in-
creased in the presence of speciﬁc concentrations of BSA,
DTT, Mg2+,a n dE D T A .
DTT was added in reaction mixture in order to in-
hibit PC-CPT, as posphatidylcholine (PC) synthesis by its
cholinephosphotransferase,PC-CPT,isknowntobestrongly
inhibited at these DTT concentrations [8, 14]. Moreover,
DTT seems to increase PAF-CPT activity.
In accordance to reported data, exogenous Mg2+ are es-
sential for enzyme action, while exogenous Ca2+ exhibit a
dose-dependent inhibitory eﬀect that was partly abolished
by the presence of EDTA. In several studies, various chelate
reagents were used in order to reduce the inhibitory eﬀect of
Ca2+onPAF-CPT[8–12,14].Itiswellknownthatthechelate
reagent EDTA prefers to bind to Ca2+ than to Mg2+in the co-
presence of these divalent cations in the reaction medium.
In the absence of exogenous Ca2+, a small range of EDTA
concentration, near 0.5mM, enhances enzyme activity by
primary binding endogenous Ca2+ than Mg2+. PAF-CPT of
HMC required a speciﬁc concentration of EDTA for its acti-
vation as both lower and higher concentrations result in its
inactivation, by either the inhibitory eﬀect of the unbounded
Ca2+ or by the reduction of Mg2+ levels from its binding with
the EDTA excess, respectively. However, in these high con-
centrations of EDTA (up to 10mM), it is possible that the
inactivation of the enzyme may be caused not only by the
binding of Mg2+, but also by the eﬀect of this chelate reagent
directly on the enzyme.
In addition, PAF-CPT exhibited classical Michaelis-
Menten kinetics with respect to both its substrates, AAG and
CDP-choline. The kinetic parameters of the enzyme (Km and
Vmax) for both substrates were similar to reported ones in
other tissues and cells [7, 8, 14, 15].
On the other hand, pefabloc (a sulfonyl-type serine pro-
tease inhibitor) had no signiﬁcant eﬀect on the enzyme ac-
tion supporting the absence of serine(s) in the active site
of the enzyme. Moreover, since Pefabloc is also PAF AH in-
hibitor [42],theformedPAF isnot aﬀectedfromthepossible
presence of PAF-AH.
Ithasbeenreportedthatseveralotherfactorscanregulate
PAF-CPT,suggestingthatthisenzymeservesasanimportant
control point in the de novo synthesis of PAF [7–12, 14]. For
example, PAF-CPT forms a complex with membrane phos-
pholipids and other protein molecules, while environmental
membrane phospholipids seem to regulate this enzyme [11].
Moreover, the neurotransmitters acetylcholine and
dopamine as well as the activators of protein kinase C 12-
myristate-13-acetate phorbol (PMA) and oleoylacetylglyc-
erol (OAG) (molecules that are implicated in several patho-
logical situations) also stimulate the de novo PAF-CPT, while
they do not activate the enzymes of the remodelling pathway
[8, 9, 43, 44].
Although it is believed that the remodeling pathway is
activated under inﬂammatory situations, the de novo path-
way, and especially PAF-CPT, may contribute to systemic8 Mediators of Inﬂammation
disorderssuchascancer[13]andcentralnervoussystemfail-
ure [12], by a slightly long-term enhance of PAF-CPT activ-
ity that could lead to steady increased levels of PAF, which
subsequently maybe implicated in systemic disorders. These
pathological situations may be reversed by inhibiting PAF-
CPT, as it was reported in two studies where the reduction
of PAF-CPT activity in human renal cell carcinoma (RCC) in
p a t i e n t sw h oh a dr e c e i v e dI F N a ,a sw e l la si nb r a i ns t r i a t u m
of rats who had received CDP-choline, resulted in reduced
levels of PAF with beneﬁcial eﬀects (inhibition of tumor pro-
gression and various disorders of the centralnervous system)
in both cases [12, 13].
In this study, preliminary in vitro experiments were con-
ducted in order to test the eﬀects of several bioactive com-
pounds of Mediterranean diet and various drugs, which are
related to several manifestations where inﬂammation dom-
inates [26, 27, 31–41, 45, 46], on PAF-CPT activity. The
results have revealed that the drugs Symvastatin and Ru-
patadine,andseveralbioactivecompoundsofMediterranean
diet, such as resveratrol (found also in wine) and polar lipids
of olive oil, olive pomace, and sea bass, exhibit an inhibitory
eﬀect on PAF-CPT of HMC in a dose-dependent manner.
Several other drugs such as INFa, Aspirin, and Tinzaparin,
as also as other bioactive compounds of Mediterranean diet
suchaspolarlipidsofseebreaminhibitedPAF-CPTinanon-
dose-dependent manner.
In conclusion, these data demonstrate that DTT-
insensitive cholinephosphotransferase (PAF-CPT) activity is
present in human mesangial cells and the biochemical prop-
erties and kinetic parameters of this enzyme of HMC were
establishedfortheﬁrsttime.Concerningpreviousdata,PAF-
CPT of mesangial cells seems to have similar properties with
PAF-CPT characterized in several cells and tissues including
human kidney. PAF production in kidney, mainly by mesan-
gial cells, is involved in the pathogenesis of renal damage.
The characterization of PAF-CPT activity in human mesan-
gial cells enables further investigation of PAF-CPT regu-
latory mechanisms, and therefore its contribution in PAF
production under physiological and pathological conditions.
Several drugs and bioactive compounds of Mediterranean
diet with beneﬁcial eﬀects in various pathological conditions
[26, 27, 31–41] seem to exhibit an inhibitory eﬀect on PAF-
CPT activity that maybe correlate with their general biologi-
cal action. It is possible that the inhibition of PAF-CPT activ-
ity in several pathological manifestations (mainly systemic)
can restore pathologically long-term slightly increased basal
PAF levels to their physiological ones, and therefore might
reverse these pathological conditions. This new point of view
need to be further studied.
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